Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis

Lancet Infect Dis. 2019 May;19(5):470. doi: 10.1016/S1473-3099(19)30168-9.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antitubercular Agents / adverse effects
  • Antitubercular Agents / therapeutic use*
  • Cohort Studies
  • Diarylquinolines / adverse effects
  • Diarylquinolines / therapeutic use*
  • Drug Therapy, Combination
  • Humans
  • Mycobacterium tuberculosis / drug effects
  • Mycobacterium tuberculosis / isolation & purification
  • Nitroimidazoles / adverse effects
  • Nitroimidazoles / therapeutic use*
  • Oxazoles / adverse effects
  • Oxazoles / therapeutic use*
  • Sputum / microbiology
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • Tuberculosis, Multidrug-Resistant / microbiology

Substances

  • Antitubercular Agents
  • Diarylquinolines
  • Nitroimidazoles
  • OPC-67683
  • Oxazoles
  • bedaquiline